A campaign to help the elderly spend the evening of their lives with dignity and without want is being launched by Pension Parishad with a dharna in Delhi from May 7th to May 11th 2012 at Jantar Mantar, New Delhi. The idea is straight and simple, and is something whose time has come. Just read on and reach the venue for more information and interviews with the campaign participants.   “One...

Here’s a “growth story” that Standard and Poor’s missed: a piece of official statistics shows good old India has grown — literally. Over 5,000sqkm of wasteland has been converted into “net” usable terrain between 2005 and 2008, according to the Wasteland Atlas of India that was released today. Even Bengal, pilloried for profligacy and other wasteful pastimes, has done its modest bit to transform wasteland. But the big battles against barren land...

The National Green Tribunal's decision to suspend the environmental clearance given to Posco vindicates the project's critics. ON March 30, the Principal Bench of the newly formed National Green Tribunal (NGT) delivered a momentous decision suspending the environmental clearance (EC) given to the South Korean transnational corporation, Posco, to set up an integrated steel plant at Paradip in Odisha's Jagatsinghpur district. The former Union Minister for Environment and Forests, Jairam...

The country is clearly shaping its legislation to promote access to medicines by fostering generic production. INDIA'S approach to the revision of its Patents Act in 2005 is a clear example of a country shaping its legislation to promote access to medicines by fostering generic production. Although World Trade Organisation (WTO) rules made it mandatory for India to put in place a patent regime for medicines by 2005, nothing obliges...

Industry reacts with caution to the grant of a compulsory licence to Natco, but cancer patients welcome it and hope for many more. THE first compulsory licence (CL) issued by the Indian patent office, to the local drug manufacturer Natco Pharma Ltd to sell the generic version of Bayer AG's anti-cancer drug Nexavar, has led to varied reactions. The landmark decision has also raised concerns about the outcome of cases...